An Update of Safety and Efficacy Results oiii Phase 1 Dose-Escalation and Expansion Study of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI), in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph plus ALL) Failing Prior TKI Therapies

被引：3

作者：

Cortes, Jorge E. ^{[1
]}

Saikia, Tapan ^{[2
]}

Kim, Dong-Wook ^{[3
,4
]}

Alvarado, Yesid ^{[5
]}

Nicolini, Franck E. ^{[6
]}

Rathnam, Krishnakumar ^{[7
]}

Khattry, Navin ^{[8
]}

Apperley, Jane F. ^{[9
]}

Deininger, Michael W. ^{[10
]}

de Lavallade, Hugues ^{[11
]}

Charbonnier, Aude ^{[12
]}

Granacher, Nikki ^{[13
]}

Gambacorti-Passerini, Carlo ^{[14
]}

Lucchesi, Alessandro ^{[15
]}

Mauro, Michael J. ^{[16
]}

Vandenberghe, Peter ^{[17
]}

Verhoef, Gregor ^{[17
]}

Whiteley, Andrew R. ^{[18
]}

Nag, Arijit ^{[19
]}

Radhakrishnan, Vivek S. ^{[19
]}

Apte, Shashikant ^{[20
]}

Yao, Siu-Long ^{[21
]}

Inamdar, Sandeep ^{[22
]}

Sreenivasan, Jayasree ^{[22
]}

Dillu, Ruchika Irene ^{[22
]}

Chimote, Geetanjali ^{[22
]}

机构：

[1] Augusta Univ, Georgia Canc Ctr, Augusta, GA USA

[2] Prince Aly Khan Hosp, Mumbai, Maharashtra, India

[3] Catholic Univ Korea, Seoul St Marys Hosp, Catholic Hematol Hosp, Coll Med,Dept Hematol, Seoul, South Korea

[4] Catholic Univ Korea, Seoul St Marys Hosp, Catholic Hematol Hosp, Coll Med, Seoul, South Korea

[5] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[6] Ctr Leon Berard, Hematol Dept, Lyon, France

[7] Meenakshi Mission Hosp & Res Ctr, Lake Area, Melur Main Rd, Madurai, Tamil Nadu, India

[8] Tata Mem Hosp, ACTREC, Dept Med Oncol, BMT Unit, Navi Mumbai, India

[9] Imperial Coll, Hammersmith Hosp, Ctr Haematol, Dept Med, London, England

[10] Univ Utah, Huntsman Canc Inst, Div Hematol & Hematol Malignancies, Salt Lake City, UT USA

[11] Kings Coll Hosp London, NHS Fdn Trust, Dept Haematol Med, London, England

[12] Inst Paoli Calmettes, Dept Hematol, Marseille, France

[13] Ziekenhuis Netwerk Antwerpen, Antwerp, Belgium

[14] Univ Milano Bicocca, Dept Med & Surg, Monza, Italy

[15] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Hematol Unit, Meldola, FC, Italy

[16] Mem Sloan Kettering Canc Ctr, Myeloproliferat Neoplasms Program, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA

[17] UZ Leuven, Dept Hematol, Leuven, Belgium

[18] Baylor Univ, Med Ctr, Dallas, TX USA

[19] Tata Med Ctr, Clin Hematol Oncol & HCT, Kolkata, India

[20] Punes Sahyadri Hosp, Pune, Maharashtra, India

[21] Sun Pharmaceut Ind Inc, Princeton, NJ USA

[22] Sun Pharma Adv Res Co Ltd, Mumbai, Maharashtra, India

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-152548

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

309

引用

页数：6

共 50 条

[41] A phase I study of INNO-406, a dual inhibitor of Abl and Lyn kinases, in adult patients with Philadelphia chromosome positive (Ph plus ) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory, or intolerant of imatinib
Craig, A. R.
Kantarjian, H. M.
Cortes, J. E.
Jones, D.
Hochhaus, A.
O'Brien, S.
Rios, M.
Zander, C.
Gleich, L.
Carroll, E. P.
Ottmann, O. G.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[42] A phase IIII study of AMN107, a novel aminopyrimidine inhibitor of bcr-abl, on a continuous daily dosing schedule in adult patients (pts) with imatinib-resistant advanced phase chronic myeloid leukemia (CML) or relapsed/refractory Philadelphia chromosome (Ph plus ) acute llymphocytic leukemia (ALL).
Giles, F
Kantarjian, H
Wassmann, B
Cortes, J
O'Brien, S
Tanaka, C
Rae, P
Mietlowski, W
Romano, A
Alland, L
Dugan, M
Albitar, M
Ottmann, O
BLOOD, 2004, 104 (11) : 10A - 11A
[43] First-in-Human Phase I Study of ELVN-001, an Oral, Selective BCR::ABL1 Tyrosine Kinase Inhibitor, in Patients With Chronic Myeloid Leukemia Who Failed Prior Tyrosine Kinase Inhibitors
Mauro, Michael
Lang, Fabian
Kim, Dong-Wook
Heinrich, Michael
Sasaki, Koji
Lyssikatos, Joe
Collins, Helen
Hochhaus, Andreas
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S345 - S345
[44] Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial
Kantarjian, Hagop M.
Kim, Dong-Wook
Pinilla-Ibarz, Javier
le Coutre, Philipp
Paquette, Ronald
Chuah, Charles
Nicolini, Franck E.
Apperley, Jane
Khoury, H. Jean
Talpaz, Moshe
DiPersio, John F.
DeAngelo, Daniel
Abruzzese, Elisabetta
Rea, Delphine
Baccarani, Michele
Muller, Martin C.
Gambacorti-Passerini, Carlo
Wong, Stephane
Lustgarten, Stephanie
Rivera, Victor M.
Clackson, Tim
Turner, Christopher D.
Haluska, Frank G.
Guilhot, Francois
Deininger, Michael W.
Hochhaus, Andreas
Hughes, Timothy P.
Goldman, John
Shah, Neil
Cortes, Jorge E.
BLOOD, 2012, 120 (21)
[45] Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors (TKIs) in patients (pts) with Philadelphia chromosome-positive (Ph plus ) leukemia: Phase 1/2 study update.
Gambacorti-Passerini, Carlo
Lipton, Jeffrey Howard
Hochhaus, Andreas
Kota, Vamsi K.
Baccarani, Michele
Durrant, Simon
Assouline, Sarit E.
Kim, Dong-Wook
Bruemmendorf, Tim H.
Leip, Eric
An, Fiona
Aguiar, Jean
Cortes, Jorge E.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[46] A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with Ph plus chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph plus acute lymphoblastic leukemia (ALL).
Giles, F. J.
Larson, R.
Le Coutre, P.
Baccarani, M.
Tavorath, R.
Alland, L.
Kantarjian, H. M.
Hughes, T.
Ottmann, O.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 346S - 346S
[47] A phase 1/2 study of SKI-606, a dual inhibitor of src and abl kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory or intolerant of imatinib.
Cortes, Jorge
Kantarjian, Hagop M.
Baccarani, Michele
Brummendorf, Tim H.
Liu, Delong
Ossenkoppele, Gert
Volkert, Angela D. G.
Hewes, Becker
Moore, Laurence
Zacharchuk, Charles
Gambacorti, Carlo
BLOOD, 2006, 108 (11) : 54A - 54A
[48] Ponatinib In Patients (pts) With Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL) Resistant Or Intolerant To Dasatinib Or Nilotinib, Or With The T315I BCR-ABL Mutation: 2-Year Follow-Up Of The PACE Trial
Cortes, Jorge E.
Kim, Dong-Wook
Pinilla-Ibarz, Javier
le Coutre, Philipp D.
Paquette, Ronald
Chuah, Charles
Nicolini, Franck E.
Apperley, Jane F.
Khoury, H. Jean
Talpaz, Moshe
DiPersio, John F.
DeAngelo, Daniel J.
Abruzzese, Elisabetta
Rea, Delphine
Baccarani, Michele
Mueller, Martin C.
Gambacorti-Passerini, Carlo
Lustgarten, Stephanie
Rivera, Victor M.
Clackson, Tim
Turner, Christopher D.
Haluska, Frank G.
Guilhot, Francois
Deininger, Michael W.
Hochhaus, Andreas
Hughes, Timothy P.
Goldman, John M.
Shah, Neil P.
Kantarjian, Hagop M.
BLOOD, 2013, 122 (21)
[49] A phase II study of dasatinib in patients with chronic myeloid leukemia (CML) in lymphoid blast crisis or Philadelphia-Chromosome positive acute lymphoblastic leukemia (Ph plus ALL) who are resistant or intolerant to imatinib: The 'START-L' CA180015 study.
Ottmann, OG
Martinelli, G
Dombret, H
Kantarjian, H
Hochhaus, A
Simonsson, B
Aloe, A
Apanovitch, A
Shah, N
BLOOD, 2005, 106 (11) : 17A - 17A
[50] A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial
Cortes, Jorge E.
Kim, Dong-Wook
Pinilla-Ibarz, Javier
le Coutre, Philipp
Paquette, Ron
Chuah, Charles
Nicolini, Franck E.
Apperley, Jane
Khoury, H. Jean
Talpaz, Moshe
DiPersio, John F.
DeAngelo, Daniel J.
Abruzzese, Elisabetta
Rea, Delphine
Baccarani, Michele
Muller, Martin C.
Gambacorti-Passerini, Carlo
Wong, Stephane
Lustgarten, Stephanie
Rivera, Victor M.
Clarkson, Tim
Turner, Christopher D.
Haluska, Frank G.
Guilhot, Francois
Deininger, Michael W.
Hochhaus, Andreas
Hughes, Timothy
Goldman, John M.
Shah, Neil
Kantarjian, Hagop M.
BLOOD, 2012, 120 (21)

← 1 2 3 4 5 →